Comparing the effectiveness of brolucizumab therapy alone versus that combined with subthreshold micropulse laser exposure in the treatment of diabetic macular edema

AO Giyasova; NR Yangieva

doi:10.31288/oftalmolzh202321620

Authors

AO Giyasova Tashkent State Dental Institute, “SIHAT KO'Z” LTD Joint Venture
NR Yangieva Tashkent State Dental Institute

DOI:

https://doi.org/10.31288/oftalmolzh202321620

Keywords:

diabetic macular edema, anti-VEGF therapy, subthreshold micropulse laser exposure

Abstract

Background: Diabetic retinopathy (DR) is a major cause of blindness in working-age individuals in the developed countries. Studies have found that diabetic macular edema (DME) is a major cause of visual impairment in patients with diabetes mellitus (DM). Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of DME.

Material and Methods: Eighty-two patients (153 eyes) with DME were divided into two treatment groups. Group 1 (37 patients, 68 eyes) was treated with injections of the anti-VEGF agent brolucizumab according to the one plus pro re nata (PRN) regimen (once plus as needed) only, whereas group 2 (45 patients, 85 eyes) received a combination of “one plus PRN” brolucizumab therapy with subthreshold micropulse laser exposure (SMPLE). Before and after treatment, a comprehensive ophthalmological examination was performed, including the best-corrected visual acuity (BCVA) and the height of retinal edema in the central fovea as assessed by optical coherence tomography. The parameters were assessed at 1, 3, 6 and 12 months after treatment.

Results: The percentage of patients with no need for additional anti-VEGF injections was substantially higher in the combined therapy group than in the monotherapy group (68.5% versus 12%, respectively, p <0.001).

Conclusion: The combination treatment (intravitreal brolucizumab combined with SMPLE) for DME was effective in 68.5% of cases within 12 months. In this way, a steady resorption of DME is accomplished through antivasoproliferative and prolonged effects of brolucizumab and the SMPLE session.

References

Volodin PL, Ivanova EV., Khrisanfova ES. [Navigational technology of targeted topographically oriented laser coagulation in the treatment of focal diabetic macular edema: First clinical results]. Modern technologies in ophthalmology. 2018;1:65-68. Russian.

Bobykin EV. Modern approaches to the treatment of diabetic macular edema. Ophthalmosurgery. 2019;1:67-76. https://doi.org/10.25276/0235-4160-2019-1-67-76

Umanets NN, Rozanova Z A, Alzein M. [Combination of intravitreal injections of ranibizumab and selective laser coagulation of retinal pigment epithelium in the treatment of diabetic cystoid macular edema]. Oftalmol Zh. 2013;3:18-22. Russian. https://doi.org/10.31288/oftalmolzh201331822

Lipatov DV, Lyshkanets OI. [Intravitreal therapy of diabetic macular edema in Russia: the current state of the problem]. Bulletin of ophthalmology. 2019;135(4):128-39. Russian. https://doi.org/10.17116/oftalma2019135041128

Okhotsimskaya TD, Zaitseva OV. [Aflibercept in the treatment of retinal diseases. Review of clinical studies]. Russian Ophthalmological Journal. 2017;2S:103-111. https://doi.org/10.21516/2072-0076-2017-10-2-103-111

Diabetic Retinopathy Clinical Research Network (DRCR.net) Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009 Mar;127(3):245-51. https://doi.org/10.1001/archophthalmol.2008.610

Busch C, Fraser-Bell S, Zur D, et al.; International Retina Group. Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study. Acta Diabetol. 2019;56(7):777-784. https://doi.org/10.1007/s00592-019-01310-z

Akkaya S, Açıkalın B, Doğan YE, Çoban F. Subthreshold micropulse laser versus intravitreal anti-VEGF for diabetic macular edema patients with relatively better visual acuity. Int J Ophthalmol. 2020; 13(10): 1606-1611. https://doi.org/10.18240/ijo.2020.10.15

Wells JA, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123:1351-1359. https://doi.org/10.1016/j.ophtha.2016.02.022

Ashraf M, Souka A, Adelman R, Forster SH. Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye (Lond) 2017;31(2):342-345. https://doi.org/10.1038/eye.2016.233

Hodzic-Hadzibegovic D., Sander B.A., Monberg T.J. et al. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines. Acta Ophthalmol. 2018;96(3):267-278. https://doi.org/10.1111/aos.13638

Brown DM, Emanuelli A, Bandello F, et al. KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. Am J Ophthalmol. 2022;238:157-172. https://doi.org/10.1016/j.ajo.2022.01.004

Fursova AZh, Derbeneva AS, Tarasov MS. Clinical efficacy of anti-angiogenic therapy for diabetic macular edema in real clinical practice (2-year results). Russian Ophthalmological Journal. 2021;14(2):42-9. https://doi.org/10.21516/2072-0076-2021-14-2-42-49

Early Treatment Diabetic Retinopathy Study research group. Early Treatment Diabetic Retinopathy Study (ETDRS). Photocoagulation for diabetic macular oedema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-806. https://doi.org/10.1001/archopht.1985.01050120030015

Kim JY, Park HS, Kim SY. Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253(12):2129-2135. https://doi.org/10.1007/s00417-015-2965-7

Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the management of diabetic macular edema by the European society of retina specialists (EURETINA). Ophthalmologica. 2017;237(4):185-222. https://doi.org/10.1159/000458539

Pankratov MM. Pulsed delivery of laser energy in experimental thermal retinal photocoagulation. Proc Soc Photo Opt Instrum Eng. 1990;1202:205-13. https://doi.org/10.1117/12.17626

Moisseiev E, Abbassi S, Thinda S, Yoon J, Yiu G, Morse LS. Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema. Eur J Ophthalmol. 2018;28(1):68-73. https://doi.org/10.5301/ejo.5001000

Su D, Hubschman JP. A review of subthreshold micropulse laser and recent advances in retinal laser technology. Ophthalmol Ther. 2017;6(1):1-6. https://doi.org/10.1007/s40123-017-0077-7

Wu Y, Ai P, Ai ZS, Xu GT. Subthreshold diode micropulse laser versus conventional laser photocoagulation monotherapy or combined with anti-VEGF therapy for diabetic macular edema: a Bayesian network meta-analysis. Biomed Pharmacother. 2018;97:293-299. https://doi.org/10.1016/j.biopha.2017.10.078

Fedchenko SA, Zadorozhnyy OS, Molchaniuk NI, Korol AR. Comparing ultrastructural changes in the rabbit chorioretinal complex after 577-nm and 532-nm laser photocoagulation. J Ophthalmol (Ukraine). 2017;6:56-71. https://doi.org/10.31288/oftalmolzh201765671